Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2C | P18825 | 2/20 | 0.57 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.57 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.57 |
| ▸ | RGS12 | O14924 | 1/20 | 0.57 |
| ▸ | GLA | P06280 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.57 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.57 |
| ▸ | HTR2A | P28223 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | THPO | P40225 | 1/20 | 0.57 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7892362 | 1.00 | ADRA2C (0.57) | ADRA2CCHRM2ADRA1ARGS12GLA | |
| Bromide SCHEMBL306447 | 0.98 | ADRA2C (0.55) | ADRA2CCHRM2ADRA1ARGS12GLA | |
| Hydrochloric Acid SCHEMBL3386662 | 0.98 | ADRA2C (0.55) | ADRA2CCHRM2ADRA1ARGS12GLA | |
| Water SCHEMBL10366292 | 0.98 | ADRA2C (0.55) | ADRA2CCHRM2ADRA1ARGS12GLA | |
| Iodide SCHEMBL6742484 | 0.81 | KDM4E (0.55) | ADRA2CCHRM2ADRA1ARGS12GLA | |
| Iodide SCHEMBL6742483 | 0.81 | KDM4E (0.55) | ADRA2CCHRM2ADRA1ARGS12GLA | |
| SCHEMBL26858844 | 0.79 | ADRA2C (0.50) | ADRA2CCHRM2ADRA1ARGS12GLA | |
| Bromide SCHEMBL25252124 | 0.78 | ADRA2C (0.48) | ADRA2CCHRM2ADRA1ARGS12GLA | |
| Bromide SCHEMBL26653709 | 0.78 | ADRA2C (0.48) | ADRA2CCHRM2ADRA1ARGS12GLA | |
| Bromide SCHEMBL6005252 | 0.78 | ADRA2C (0.48) | ADRA2CCHRM2ADRA1ARGS12GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090197919-A1 | Novel Method for Preparation of Ammonium Salts of Esomeprazole | ASTRAZENECA AB (SE) | 2009-08-06 | — | — | US | claimed |
| EP-2048144-A1 | Process for the preparation of optically pure omeprazole via salt formation with a chiral amine | KRKA, tovarna zdravil, d.d., Novo mesto (SI) | 2009-04-15 | — | — | EP | claimed |
| EP-0244717-A2 | Process for the preparation of 2,3-epoxyamides | BAYER AG (DE) | 1987-11-11 | — | — | EP | claimed |
| EP-2029574-B1 | NOVEL METHOD FOR PREPARATION OF AMMONIUM SALTS OF ESOMEPRAZOLE | ASTRAZENECA AB (SE) | 2010-12-01 | — | — | EP | disclosed |
| US-7776582-B2 | for gas chromatography; identifying an optically enhanced chiral ionic liquid (OCIL) for enantiomeric resolution | SIGMA-ALDRICH CO. (US) | 2010-08-17 | — | — | US | disclosed |
| US-20090197919-A1 | Novel Method for Preparation of Ammonium Salts of Esomeprazole | ASTRAZENECA AB (SE) | 2009-08-06 | — | — | US | disclosed |
| US-20090145197-A1 | Optically Enhanced Chiral Ionic Liquids | SIGMA-ALDRICH CO. NEWCO INC. | 2009-06-11 | — | — | US | disclosed |
| EP-2048144-A1 | Process for the preparation of optically pure omeprazole via salt formation with a chiral amine | KRKA, tovarna zdravil, d.d., Novo mesto (SI) | 2009-04-15 | — | — | EP | disclosed |
| EP-1765781-A2 | OPTICALLY ENHANCED CHIRAL IONIC LIQUIDS | Sigma-Aldrich Co. (US) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006017148-A2 | OPTICALLY ENHANCED CHIRAL IONIC LIQUIDS | SIGMA-ALRICH CO. (US) | 2006-02-16 | — | — | WO | disclosed |
| US-20060014955-A1 | Optically enhanced chiral ionic liquids | ADVANCED SEPARATION TECHNOLOGIES INC. (US) | 2006-01-19 | — | — | US | disclosed |
| EP-0244717-A2 | Process for the preparation of 2,3-epoxyamides | BAYER AG (DE) | 1987-11-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014955-A1 | Optically enhanced chiral ionic liquids | GCG, INF2, ELOVL3 | ADRA2C 1874/4885CHRM2 747/4885ADRA1A 2918/4885 |
| US-20090197919-A1 | Novel Method for Preparation of Ammonium Salts of Esomeprazole | ATP6AP1, ATP6V1G1, ATP6V1A | ADRA2C 1778/4885CHRM2 2914/4885ADRA1A 1732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.